Latest news and press releases about AN2 Therapeutics, Inc. (ANTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
Price
| Price | $4.90 |
| Market Cap | $176M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.89 |
| EV / EBITDA | -3.96 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -53.52% |
| Return on Invested Capital | -51.01% |
| Return on Assets | -44.41% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BOLD · IBIO · INTS · ITRM · NXTC · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of ANTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks